Finanzen von Attovia Therapeutics Inc (ATTO)ATTOAttovia Therapeutics Inc

Evaluating the bottom line, Attovia Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -4845.11%, while the net margin is -4597.11%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively ATTO converts its operational activities into shareholder value.

In the context of the broader market, ATTO competes directly with industry leaders such as CADL and PRME. With a market capitalization of $626.79M, it holds a significant position in the sector. When comparing efficiency, ATTO's gross margin of 100.00% stands against CADL's N/A and PRME's 100.00%. Such benchmarking helps identify whether Attovia Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Attovia's financial performance shows a concerning trend with a net loss of $20.69 million in Q2 2026 and a gross margin of 100% only in that quarter, indicating reliance on specific revenue streams. The total revenue for Q2 was only $450,000, which is insufficient to cover losses.